PLCB1 and myelodysplastic syndrome: They observed that responsive MDS patients displayed higher levels of PLCB1 during clinical improvement, as well as increased expression levels of Cyclin D3, one of the molecular targets of PI-PLCβ1, a key regulator of G1/S cell cycle phase and hematopoietic differentiation [60].